Arpit Parmar, Dinesh Prasad Sahu, Priyamadhaba Behera
{"title":"Burden of alcohol use and inclusion of alcohol use disorder medications in the essential medicine lists across 132 countries: An observational study.","authors":"Arpit Parmar, Dinesh Prasad Sahu, Priyamadhaba Behera","doi":"10.1016/j.alcohol.2024.02.007","DOIUrl":"https://doi.org/10.1016/j.alcohol.2024.02.007","url":null,"abstract":"<p><p>Harmful use of alcohol effects the health of the population. The treatment coverage of alcohol use disorders (AUD) varies among countries. The study aimed to determine the inclusion of AUD medicines in various national Essential Medicine Lists (EMLs) and its association with alcohol consumption. It was a secondary data analysis of alcohol consumptions and AUD related medicines in EML. Data were extracted from the WHO Global Essential Medicines database and the WHO Global Status Report on Alcohol and Health 2018. Data were extracted for 194 countries. Only 132 of 194 countries (68.0%) had EML, and among the 132 countries only 27.3% had included AUD medicines in their EML. Only 36 countries had included any of the AUD medicines in their EML. Disulfiram was included by 23 countries, while Acamprosate and Naltrexone was included by only four and 19 countries, respectively. Among the countries, 36.1% were from upper-middle income countries and 16.65 from low-income countries. The inclusion of AUD medicines in national EML was neither associated with alcohol consumption parameters nor the alcohol consumption related policy parameters. Considering the high prevalence of AUD and its complications, there is an urgent need to focus on including AUD medicines in national EML for making AUD treatment available and accessible across the world.</p>","PeriodicalId":93864,"journal":{"name":"Alcohol (Fayetteville, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139998444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Palaniswamy Ramaswamy, Athira S V, Pratibha Misra, V S Chauhan, Arka Adhvaryu, Anurodh Gupta, Ankita G, Sibin M K
{"title":"Circulating microRNA profiling identifies microRNAs linked to prediabetes associated with alcohol dependence syndrome.","authors":"Palaniswamy Ramaswamy, Athira S V, Pratibha Misra, V S Chauhan, Arka Adhvaryu, Anurodh Gupta, Ankita G, Sibin M K","doi":"10.1016/j.alcohol.2024.01.003","DOIUrl":"https://doi.org/10.1016/j.alcohol.2024.01.003","url":null,"abstract":"<p><strong>Background: </strong>MicroRNAs are abundant in serum and have emerged as important regulators of gene expression, implicating them in a wide range of diseases. The purpose of this study was to discover and validate serum miRNAs in prediabetes associated with alcohol dependence syndrome (ADS).</p><p><strong>Method: </strong>Serum samples from ADS patients with or without prediabetes and normoglycemic controls were subjected to microarray. Validation of identified candidate miRNAs was performed by RT-qPCR. Additionally, GO and KEGG pathway analyses were carried out to uncover target genes anticipated to be controlled by the candidate miRNAs.</p><p><strong>Results: </strong>Notably, 198, and 172 miRNAs were differentially expressed in ADS-patients with or without prediabetes compared to healthy controls, and 7 miRNAs in ADS-patients with prediabetes compared to ADS-normoglycemic patients, respectively. Furthermore, hsa-miR-320b and hsa-miR-3135b were differentially expressed exclusively in ADS-patients with prediabetes, and this was further validated. Interestingly, GO and KEGG pathway analysis revealed that genes predicted to be modulated by the candidates were considerably enriched in numerous diabetes-related biological processes and pathways.</p><p><strong>Conclusion: </strong>Our findings revealed that ADS-patients with or without prediabetes have different sets of miRNAs compared to normoglycemic healthy subjects. We propose serum hsa-miR-320b and hsa-miR-3135b as potential biomarkers for the diagnosis of prediabetes in ADS-patients.</p>","PeriodicalId":93864,"journal":{"name":"Alcohol (Fayetteville, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139547777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Magda Malewska-Kasprzak, Agnieszka Permoda-Pachuta, Maria Skibińska, Marta Malinowska-Kubiak, Filip Rybakowski, Monika Dmitrzak-Węglarz
{"title":"Investigation of serum BDNF levels in alcohol withdrawal syndrome with and without other medical co-morbidities.","authors":"Magda Malewska-Kasprzak, Agnieszka Permoda-Pachuta, Maria Skibińska, Marta Malinowska-Kubiak, Filip Rybakowski, Monika Dmitrzak-Węglarz","doi":"10.1016/j.alcohol.2023.12.006","DOIUrl":"10.1016/j.alcohol.2023.12.006","url":null,"abstract":"<p><strong>Introduction: </strong>Consequences of alcohol use disorder (AUD) are associated with mental and somatic burdens that result in alcohol withdrawal syndrome (AWS), with 30% of AWS cases leading to life-threatening delirium tremens (DTs). So far, biomarkers for tracking abstinence syndrome that are useful in clinical practice have yet to be detected. Current research focuses on brain-derived neurotrophic factor (BDNF) effects on neurogenesis, modulation of plasticity, and its role in the pathogenesis of AWS and DTs.</p><p><strong>Aims: </strong>The present study aimed to assess pro-BDNF and BDNF concentrations in a group of patients with AWS. Changes in BDNF and prof-BDNF were also evaluated with attention to subgroups of patients with coexisting mental and somatic disorders, with a particular emphasis on the presence or absence of DTs.</p><p><strong>Results: </strong>The AWS group had a higher concentration of BDNF and a lower concentration of pro-BDNF compared to the control group, and BDNF increased during 7 days of hospitalisation. Patients with comorbid psychiatric disorders had higher levels of pro-BDNF than those without disease and also had higher levels of BDNF at the end of the study than at the beginning. On the other hand, patients with coexisting somatic diseases had higher levels of pro-BDNF at the beginning than at the end of the study, while patients with delirium had higher BDNF levels at the end of the study than at the beginning.</p><p><strong>Conclusions: </strong>The obtained results indicate that pro-BDNF and BDNF may be useful markers for the course of withdrawal syndrome. In particular, BDNF showed an association with the development of delirium complications. The authors are aware of several limitations of the work only men in the SG, different age between SG and CG.</p>","PeriodicalId":93864,"journal":{"name":"Alcohol (Fayetteville, N.Y.)","volume":" ","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139492735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
